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Abstract
Background: Neuroinflammation and demyelination have been suggested as mechanisms causing HIV-1
associated neurocognitive disorder (HAND). This cross-sectional cohort study explores the potential role of
antibodies to myelin oligodendrocyte glycoprotein (MOG), a putative autoantigen in multiple sclerosis, in the
pathogenesis of HAND.
Methods: IgG antibodies against MOG were measured by ELISA in sera and cerebrospinal fluid (CSF) of 65 HIV-
positive patients with HAND (n = 14), cerebral opportunistic infections (HIVOI, n = 25), primary HIV infection (HIVM,
n = 5) and asymptomatic patients (HIVasy, n = 21). As control group HIV-negative patients with bacterial or viral
CNS infections (OIND, n = 18) and other neurological diseases (OND, n = 22) were included. In a subset of HAND
patients MOG antibodies were determined before and during antiviral therapy.
Results: In serum, significantly higher MOG antibody titers were observed in HAND compared to OND patients. In
CSF, significantly higher antibody titers were observed in HAND and HIVOI patients compared to HIVasy and OND
patients and in OIND compared to OND patients. CSF anti-MOG antibodies showed a high sensitivity and
specificity (85.7% and 76.2%) for discriminating patients with active HAND from asymptomatic HIV patients. MOG
immunopositive HAND patients performed significantly worse on the HIV dementia scale and showed higher viral
load in CSF. In longitudinally studied HAND patients, sustained antibody response was noted despite successful
clearance of viral RNA.
Conclusions: Persistence of MOG antibodies despite viral clearance in a high percentage of HAND patients
suggests ongoing neuroinflammation, possibly preventing recovery from HAND.
Background
HIV encephalopathy (HIVE) leads to dementia and
motor disorder and is the major direct central nervous
system (CNS) manifestation of advanced HIV-1 infec-
tion. Since the availability of combination antiretroviral
therapy (cART) its incidence has decreased, but to a les-
ser extent than the incidence of extra-cerebral AIDS-
manifestations [1]. With the increasing life expectancy
of HIV-infected individuals the prevalence of HIV asso-
ciated neurocognitive disorder (HAND) has risen to 20-
50% [2]. While it is generally accepted that HAND is
treatable, the extent and sustainability of the effects of
cART on cerebral functioning are still unclear. There is
accumulating evidence of chronically progressive and, at
times, fluctuating cognitive impairment in patients with
effective cART in terms of suppression of plasma viral
load [3,4], compatible with the notion of quiescent and
active disease [5]. While HIV is the agens movens of
HIVE, it does not damage neuronal cells directly.
Rather, a plethora of cellular and molecular immunolo-
gical mechanisms leads to neurological dysfunction [6].
Demyelination has early been recognized as a feature in
the pathological and radiological appearance of HIVE
[7,8], and cases with early-stage HIV infection clinically
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[9]. Myelin breakdown products and antibodies against
them have been implicated in this context. In particular
myelin basic protein has been suggested to be of prog-
nostic significance [10,11].
Another myelin protein that has been extensively stu-
died in MS is myelin oligodendrocyte glycoprotein
(MOG) [12]. MOG is a quantitatively minor type I
transmembrane protein exclusively expressed in the
CNS, and its extracellular domain has been identified as
a main target for immune responses in experimental
allergic encephalitis (EAE), an animal model for MS
[13]. However, in humans antibodies against MOG are
mainly found in patients with acute demyelinating ence-
phalomyelitis (ADEM) or childhood MS [14-16] whereas
their value in adult MS is still under debate [17]. Anti-
MOG antibodies are also detected in infectious diseases
of the CNS [18], and their presence correlates with the
titers of antibodies to Epstein Barr Virus (EBV) [19]. To
our knowledge, this cross-sectional cohort study is the
first to evaluate the potential role of MOG antibodies in
cerebrospinal fluid (CSF) and serum of patients with
HIV as markers for disease course and response to anti-
viral therapy.
Methods
Patient characteristics
Within a six-years period 65 consecutive HIV patients
were recruited at the University Hospital Hamburg, Ger-
many. The primary care-giving physicians of the Medi-
cal Department presented the patients to the
Neurological Department for the clinical and diagnostic
workup for potential neurological disease, and a propor-
tion of subjects took part in an observational study for
CNS manifestations of HIV infection. The visits were
done by a single neurologist (CE) experienced in the
treatment of HIV infection. Patients underwent lumbar
puncture (LP) for the evaluation of neurological mani-
festations of HIV infection or as part of the observa-
tional study. In subjects with longitudinal sampling LP
was performed prior to initiation or change of therapy
and at variable intervals thereafter with a minimum of
one follow-up lumbar puncture during cART. Peripheral
blood samples were obtained in parallel with lumbar
puncture. Cognitive impairment was quantified by the
HIV dementia scale (HDS) [20]. HIV patients were clas-
sified in four groups for further analyses: The “HIV
associated neurocognitive disorder group” (HAND) con-
sisting of 14 patients with the typical clinical phenotype
of HIV associated neurocognitive disorder and exclusion
of differential diagnoses, the “HIV with opportunistic
infection group” (HIVOI) comprising 25 patients with a
cerebral opportunistic infection (CNS toxoplasmosis n =
10; progressive multifocal leukoencephalopathy n = 6,
cryptococcal meningitis n = 5, neurosyphilis n = 2, cyto-
megalovirus encephalitis n = 2), the “HIV meningitis
group” (HIVM) including 5 patients with aseptic menin-
gitis in the context of serologically proven primary HIV
infection, and the “HIV asymptomatic group” (HIVasy)
with 21 HIV-infected patients in whom neurological
involvement was excluded by clinical, laboratory (includ-
ing spinal tap) and imaging findings.
HIV-negative controls with normal cognitive function
were recruited at the Department of Neurology, Innsbruck
Medical University. Subjects with other infectious neurolo-
gical diseases (OIND) and non-inflammatory other neuro-
logical diseases (OND) served as another control group.
The 18 OIND patients suffered from bacterial meningitis
(pneumococci n = 5, meningococci n = 5, staphylococcus
aureus n = 1, beta-hemolytic streptococci n = 1, and unde-
termined microorganism n = 2) and herpes simplex-1
meningoencephalitis (n = 4). The 22 OND patients were
diagnosed with pseudotumor cerebri, migraine, psycho-
genic neurological symptoms, sinus venous thrombosis,
vascular leukoencephalopathy, herniated vertebral disc,
transient ischemic attack, spastic paraparesis, multiple sys-
tem atrophy, neuropathic pain syndrome, cerebellar
infarction, brain tumor, focal dystonia, and ischemic trans-
verse spinal cord syndrome. The study was approved by
the respective ethics committees of Hamburg and
Innsbruck Medical University, and all patients declared
their informed consent. CSF cytology, CSF white and red
blood cell count, total protein, CSF to serum albumin quo-
tient (Qalb i.e. [Alb]CSF/[Alb]Ser × 1000), and intrathecal
production of immunoglobulin G (IgG-index) was ana-
lyzed in every subject. Samples with a red blood cell count
of more than 20/μl in the CSF were excluded.
Antibody analysis
The presence of IgG antibodies to recombinant human
MOG extracellular Ig domain (amino acids 1-125) pro-
duced in E. coli bacteria was determined by ELISA, as
described previous l y[ 1 9 , 2 1 ] .I ns e r u m ,av a l u eo f0 . 6
optical density (OD) units for anti-MOG IgG was
d e f i n e da sc u t o f ff o rap o s i t i v er e s u l t ,a sd e r i v e df r o ma
pool of external reference samples from healthy indivi-
duals [21].
Statistical analyses
Patient characteristics were compared between groups
by ANOVA (age), Kruskal-Wallis test (CSF white blood
cell count, Qalb, IgG-index), Chi-square test (sex, pre-
sence of MOG antibodies) or Wilcoxon-rank-sum test
(HDS) depending on the data type and distribution.
Optical density values for MOG antibodies were com-
pared between groups by Kruskal-Wallis test, post-hoc
analysis was done by Dunn’s Multiple Comparison Test.
Repeated measures data from longitudinally studied
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OD values for MOG antibodies) was logarithmically
transformed and modeled by generalized estimation
equations (GEE). For evaluating the discriminatory
power of MOG antibodies receiver operator characteris-
tic (ROC) curves were drawn and cut-off points were
chosen equally weighting sensitivity and specificity. Cal-
culations were performed with SPSS 16 (SPSS, Chicago,
IL, USA) and GraphPad Prism 5.00 (GraphPad Software,
San Diego, CA, USA).
Results
A total of 65 subjects with HIV infection were included
in this study. For the assignment to groups see Methods.
Demographic, clinical and CSF data of the respective
patient groups are given in table 1.
MOG antibody response is elevated in HIV patients with
CNS involvement
The highest percentage of patients positive for anti-
MOG antibodies in serum was observed in the HAND
group (50.0%, table 1). In the HIVOI and OIND group
40.0% and 33.3% of patients were anti-MOG antibody
positive, respectively. Only one patient (20.0%) with
HIVM, one patient (4.5%) in the OND group and one
patient (4.8%) of the HIVasy group were positive for
anti-MOG antibodies. This difference was statistically
highly significant (p = 0.003).
The concentrations of anti-MOG IgG, as determined
by the OD values, were also significantly different
between groups (p = 0.006). Post hoc analyses yielded
significantly higher MOG-IgG OD values in the
HAND group compared to the OND group (p < 0.01,
figure 1A).
Unlike for serum, there is no established cut-off value
for antibody reactivity in CSF. Therefore OD values
were compared, yielding a highly significant difference
between groups (p < 0.001, figure 1B). Post hoc analyses
showed significantly higher MOG-IgG OD values in
HAND and HIVOI patients compared to HIVasy (p <
0.05 and p < 0.01) and OND (both p < 0.001) patients.
In OIND patients also higher MOG-IgG OD values
were observed compared to OND patients (p < 0.01).
MOG antibodies discriminate HAND from asymptomatic
HIV patients
In order to further elaborate the clinical significance of
anti-MOG antibodies, receiver operator characteristic
(ROC) curves where drawn for discriminating HAND
from asymptomatic HIV patients. The area under the
curve (AUC) was 0.881 (confidence interval 0.766-0.996)
for CSF anti-MOG IgG antibodies and 0.789 (confidence
interval 0.617-0.961) for serum anti-MOG IgG antibo-
dies. The AUC for the IgG-index was 0.810 and 0.806
for the albumin quotient, respectively. In CSF, a cut-off
value of 0.14 yielded a sensitivity of 85.7% and a specifi-
city of 76.2% for discriminating HIV positive patients
with active HAND from asymptomatic HIV patients. In
s e r u m ,ac u t - o f fv a l u eo f0 . 2 7 yielded a sensitivity of
85.7% and a specificity of 47.6%.
MOG antibodies correlate with grade of dementia in
HAND
In eight patients with HAND the HDS was assessed
during a total of 17 visits.
The baseline HDS result was significantly more
impaired in subjects with detectable anti-MOG serum
IgG antibodies (median HDS = 2, range = 2-3) as com-
pared to the MOG seronegative subjects (median HDS
= 16, range = 10-16, p = 0.021), i.e. these patients were
more severely demented.
MOG antibodies are associated with CSF viral load
Plasma and CSF viral load was available for 13 patients
during a total of 40 visits. Viral load in CSF was signifi-
cantly higher in anti-MOG antibody positive than in
anti-MOG negative serum samples (p < 0.001, GEE,
figure 2A, figure 3). Viral load in plasma, however, was
not significantly different between anti-MOG antibody
positive and negative serum samples (figure 2B). In addi-
tion, there was no association between CD4
+ cell counts
and MOG serum antibody positivity (data not shown).
Table 1 Patient characteristics
HAND HIVOI HIVM HIVasy OIND OND p-value
n 14 25 5 21 18 22
age (mean and STD) 45.2 (11.9) 41.5 (10.4) 33.8 (12) 35.9 (11.2) 51.6 (19.2) 42.6 (12.4) 0.007
female gender (%) 3 (21.4%) 5 (20.0%) 2 (40.0%) 0 (0.0%) 9 (50.0%) 15 (65.2%) < 0.001
CSF cells/μl (mean and STD) 5.9 (7.5) 12.9 (15.1) 65.9 (94.9) 2.3 (2.3) 2313 (3051) 2 (2) < 0.001
IgG-index (mean and STD) 0.97 (0.39) 0.88 (0.27) 0.60 (0.14) 0.63 (0.15) 0.82 (0.48) 0.48 (0.07) < 0.001
Qalb (mean and STD) 9.3 (3.9) 10.8 (6.6) 12.9 (8.8) 6.8 (5.7) 47.3 (48.8) 5.6 (2.3) < 0.001
MOG IgG serum positivity (%) 7 (50.0%) 10 (40.0%) 1 (20.0%) 1 (4.8%) 6 (33.3%) 1 (4.5%) 0.003
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All patients with HAND were initially cART naïve. Ten
patients underwent documented follow up visits with
repeated CSF/blood sampling. In seven patients longitu-
dinal viral load data were available. Anti-MOG antibodies
and CSF viral load in these patients are shown in figure 3.
Most patients showed sustained anti-MOG IgG response
in serum despite successful clearance of viral RNA from
CSF (figure 3). Initiation of cART was followed by an
initial increase in the OD values in some patients. With
continuing treatment anti-MOG antibodies decreased
and became negative after clearance of viral RNA in four
patients. The mean time interval to seroconversion in
these patients was 447 days (range 179-782 days). The
time dependent decrease of anti-MOG antibodies after
initiation of cART was supported by a statistically highly
significant effect of time of sampling on antibody concen-
tration in the GEE model (p < 0.001). The mean time
interval between the visits was 128 days (range 13-673
days). Only three out of 10 patients did never show anti-
bodies against MOG.
Figure 1 IgG antibody response to MOG in serum and CSF.
Serum (A) and CSF (B) IgG antibody response to MOG in patients
with HIV associated neurocognitive disorder (HAND), HIV patients
with opportunistic infections of the CNS (HIVOI), HIV meningitis
(HIVM), asymptomatic HIV infection (HIVasy), other infectious
neurological diseases (OIND) and other neurological diseases (OND).
Kruskal Wallis test (A: p < 0.01, B: p < 0.001). Dunn’s post hoc test
yielded a significant difference between HAND and OND patients (p
< 0.01, A). The dotted line indicates a cut-off value of 0.6 OD, which
is considered as serum immunopositivity for MOG IgG. In CSF
samples Dunn’s post hoc test yielded a significant difference of
HAND and HIVOI patients compared to HIVasy (p < 0.05 and p <
0.01) and OND patients (both p < 0.001) and OIND compared to
OND patients (p < 0.01). Data is shown on a logarithmic scale; the
horizontal bar represents the median.*, p < 0.05; **, p < 0.01; ***, p
< 0.001.
Figure 2 Viral load in CSF and plasma samples. Viral load in CSF
(A) and plasma samples (B) (virus copies per milliliter) stratified for
positive serum anti-MOG IgG antibodies. Data is shown on a
logarithmic scale, samples below the detection limit are shown as 1
virus copy/ml. The horizontal bar represents the median. Repeated
measures data was modeled by generalized estimation equations.
***, p < 0.001.
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associated neurocognitive disorder (HAND) documented follow-up visits and available CSF viral load data. The dotted line indicates a cut-off
value of 0.6 OD, which is considered as serum immunopositivity for MOG IgG. Groupwise repeated measures data was modeled by generalized
estimation equations and showed a highly significant effect (p < 0.001) of time of sampling on the concentration of anti-MOG antibodies.
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successful cART
MRI scans and OD values for MOG IgG antibodies of
one patient with HIV associated dementia (HAD) are
shown in figure 4. This 35 year old male patient with
HAD initially presented with severe dementia (HDS of
2), a CD4+ cell count of 145/μla n dap l a s m aa n dC S F
viral load of 58000 and 450000 viral copies/ml, respec-
tively. After initiation of cART, rapid elimination of the
virus in plasma but considerably delayed clearance from
CSF was noted. Although the patient had clinically
improved 20 weeks after the first visit, the MRI scan
showed a deterioration of leukoencephalopathy paral-
leled by a sharp increase of OD values for MOG IgG
antibodies.
Discussion
The pathophysiology of HIVE remains incompletely
understood. While in the cART era the incidence of
AIDS-defining conditions showed a dramatic decrease,
AIDS dementia complex is still observed in a compar-
ably high percentage of patients and despite successful
viral clearance [22]. Ongoing autoimmune mechanisms
have been suggested as an explanation for this discre-
pancy [6]. Besides activation of brain microglia, comple-
ment-mediated mechanisms have been implicated in the
development of neurological dysfunction [23,24]. Com-
plement is readily activated by antibodies binding to cel-
lular epitopes. With respect to autoimmune phenomena,
CSF antibody responses to CNS autoantigens such as
myelin basic protein (MBP) have been demonstrated
[11,25]. These responses seemed to be more prominent
in the CSF of neurologically symptomatic HIV subjects.
However an association with serum antibodies was not
found [25,26].
In our study, we found higher anti-MOG reactivity in
CSF and serum of patients with HAND as compared to
OND patients. For autoantibodies to CNS antigens it is
generally accepted that some degree of brain tissue
damage as well as an increased blood-brain-barrier per-
meability is needed for the antigen to be presented to
the immune system. Such a lesion to cerebral tissue
m a yb ea s s u m e di na c u t eH I V - a ssociated opportunistic
CNS-infections as well as in non-HIV-associated menin-
gitis/encephalitis (the groups HIVOI and OIND). There-
fore, our finding that anti-MOG antibodies were highest
in the serum and CSF of patients with HAND is some-
what surprising, as accepted signs of inflammation such
as CSF pleocytosis and contrast enhancement on MRI
are conspicuously absent in HIVE.
A significant finding is the higher values of CSF and
(less so) serum MOG antibodies in the HAND group as
compared to the group of asymptomatic HIV subjects.
As HIV invades the CNS in every infected subject from
e a r l yo n ,t h ep r e s e n c eo ft h ev i r u so ni t so w nc a n n o t
account for the higher MOG antibody titers in HAND
subjects. In addition, our finding of higher MOG anti-
body titers in more demented patients adds to the
impression that anti-MOG antibody formation, in the
absence of grossly destructive inflammation, may be a
relevant biomarker for HAND.
Another finding of clinical importance is the high dis-
criminatory power of CSF anti-MOG antibodies (AUC =
0.881) compared to other routine CSF parameters in
ROC analyses. Importantly, a cut-off value of 0.14 for
CSF anti-MOG antibodies was highly sensitive and spe-
cific in distinguishing patients with active HAND from
asymptomatic HIV patients. Since opportunistic infec-
tions and HIV-associated meningitis are easily detected
by an elevated CSF cell count, elevated CSF anti-MOG
antibodies could aid the clinician in the sometimes diffi-
cult diagnosis of HAND.
Our result of an association of anti-MOG antibody
titers with the viral load in CSF, but not plasma, sug-
gests that the immunological activity in the CNS may be
d i s s o c i a t e df r o mi m m u n ep rocesses in the systemic
Figure 4 Case report. Case report: increasing leukoencephalopathy
under successful cART. MR scans and OD values for MOG IgG of
one patient with HAND are shown.
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nized correlation of HIV dementia with CSF, but not
plasma viral load [27], and the delayed suppression of
CSF viral replication upon initiation of cART in HAND
patients [28].
With successful treatment of a microbial assault to the
brain, as represented in our study by suppression of HIV
production in the CSF and plasma, one would expect
the stimulus for the production of autoantibodies to
eventually disappear. Accordingly, in microbial meningi-
tis and systemic inflammatory diseases anti-MOG anti-
bodies have been shown to be transient [18]. In this
respect, the persistence of MOG antibodies over months
to years in six of our patients and, even more so, the
emergence of MOG antibodies in one patient only after
initiation of cART is of particular interest.
A related observation was the increase of anti-MOG
antibodies in the early samples after initiation of cART
despite decrease of the plasma and (to a lesser extent)
CSF viral load. This was particularly pronounced in one
patient in whom follow-up brain MRI showed an inter-
mittent marked increase in white matter lesions in con-
trast to clinical improvement of his HAND.
The discordance between anti-MOG antibodies and
viral suppression in many patients suggests that immu-
nological mechanisms are relatively independent from
virus concentrations. Eden et al. showed sustained
immunologic activity as judged by persistently elevated
CSF neopterin levels in HIV-positive individuals with
long-term suppression of plasma and CSF viral load
[29].
In the patient presented as case vignette the progres-
sive white matter lesions in parallel to increasing anti-
MOG antibodies might be regarded as an immune
reconstitution phenomenon in response to CNS autoan-
tigens similar to the clinically overt immune reconstitu-
tion syndromes that have been described in HIV
patients with opportunistic infections upon start of
treatment [30].
This study has some limitations. First, the retrospec-
tive collection of some of the data may have introduced
bias. While HAND, HIVOI and the OND group showed
comparable age distribution, patients with primary HIV
infection and asymptomatic HIV patients were younger
and OIND patients were older. Although an age-depen-
dent effect of immune response to myelin components
cannot be excluded, it has so far not been observed by
others [18,21]. In addition, the main difference in serum
anti-MOG activity was observed between HAND and
OND patients who were well matched. Hence, we are
confident that this difference should not adversely influ-
ence the interpretation of the data. Second due to the
limited number of included HIV positive patients, the
study was underpowered to detect differences among
subgroups of HAND patients. Further studies will have
to address the question if anti-MOG antibodies are able
to differentiate HAND patient with asymptomatic neu-
rocognitive impairment or mild neurocognitive disorder
from neurologically asymptomatic patients as it was the
case in patients with HAD in the current study. Third,
in MS the role of MOG antibodies is still under debate,
and a number of recent studies suggest that antibodies
to native MOG might only be pathogenic in patients
with acute disseminated encephalomyelitis (ADEM) or
childhood MS [14-16], whereas they are an epiphenome-
non in “classical MS” that might be related to ongoing
tissue damage [18,31] or EBV infection [19]. In this
study we have used recombinant human MOG extracel-
lular Ig domain (amino acids 1-125) produced in E. coli
bacteria to determine anti-MOG antibodies by ELISA.
This recombinant protein was refolded after purification
[32] and has been widely used for immunological studies
in patients and animal models (reviewed by [13] and
[12]) and for the determination of the three-dimensional
structure of MOG [33]. Recent data indicate that patho-
genic antibodies recognize the physiological membrane
topology and glycosylation pattern of MOG [34],
whereas antibodies to the MOG preparation used in the
current study reflect CNS inflammation and a secondary
response to myelin debris rather than a pathogenic anti-
body response. However, the exact role of antibodies to
surface exposed conformational epitopes and glycosy-
lated MOG in HAND require further studies.
Conclusions
In conclusion, our study demonstrates high rates of ser-
opositivity and high titers of CSF antibodies to MOG in
patients suffering from HAND as compared to asympto-
matic HIV-infected and unifected subjects. In a propor-
tion of HAND patients these autoantibodies persist or
even develop upon initiation of cART with successful
clearance of viral RNA from CSF, suggesting that anti-
body-mediated mechanisms of brain damage might play
a role in the neuropathogenesis of AIDS. In addition,
determination of serum anti-MOG antibodies might be
a new non-invasive marker for the discrimination of
active versus quiescent neuroinflammation in the con-
text of HIVE.
Acknowledgements
This work was supported by a grant of the Joachim Kuhlmann Foundation
to Christian Eggers and by internal funding of Innsbruck Medical University.
Author details
1Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
2Department of Neurology, Krankenhaus Barmherzige Brüder, Linz, Austria.
Authors’ contributions
PL, ES and CE had the idea and designed the study. BK and MM performed
the sample analyses. MR supervised all laboratory analyses. PL and MR
Lackner et al. Journal of Neuroinflammation 2010, 7:79
http://www.jneuroinflammation.com/content/7/1/79
Page 7 of 8performed the data analyses. TB helped with the design of the study and
the interpretation of the results. PL, ES and TB recruited control patients, CE
recruited all HIV patients. PL and CE drafted the manuscript. All authors have
read and approved the final version of the manuscript.
Competing interests
There is neither a relationship nor a support which might be perceived as
constituting a conflict of interest of any of the authors.
Received: 20 September 2010 Accepted: 17 November 2010
Published: 17 November 2010
References
1. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ: Marked improvement in
survival following AIDS dementia complex in the era of highly active
antiretroviral therapy. AIDS 2003, 17:1539-1545.
2. Sacktor N: The epidemiology of human immunodeficiency virus-
associated neurological disease in the era of highly active antiretroviral
therapy. J Neurovirol 2002, 8(Suppl 2):115-121.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al:
Updated research nosology for HIV-associated neurocognitive disorders.
Neurology 2007, 69:1789-1799.
4. Cysique LA, Maruff P, Brew BJ: Prevalence and pattern of
neuropsychological impairment in human immunodeficiency virus-
infected/acquired immunodeficiency syndrome (HIV/AIDS) patients
across pre-and post-highly active antiretroviral therapy eras: a combined
study of two cohorts. J Neurovirol 2004, 10:350-357.
5. Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, et al:
Biomarkers of HIV-1 CNS infection and injury. Neurology 2007,
69:1781-1788.
6. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat
Rev Immunol 2005, 5:69-81.
7. Schmidbauer M, Huemer M, Cristina S, Trabattoni GR, Budka H:
Morphological spectrum, distribution and clinical correlation of white
matter lesions in AIDS brains. Neuropathol Appl Neurobiol 1992,
18:489-501.
8. McArthur JH, McArthur JC: Neurological manifestations of acquired
immunodeficiency syndrome. J Neurosci Nurs 1986, 18:242-249.
9. Berger JR, Tornatore C, Major EO, Bruce J, Shapshak P, Yoshioka M, et al:
Relapsing and remitting human immunodeficiency virus-associated
leukoencephalomyelopathy. Ann Neurol 1992, 31:34-38.
10. Mastroianni CM, Liuzzi GM, Vullo V, Jirillo E, Delia S, Riccio P: Detection of
cerebrospinal fluid antibodies against myelin basic protein in patients
with AIDS dementia complex. Mol Chem Neuropathol 1991, 14:227-236.
11. Silva AA, Camara V, Quirico-Santos T: Intrathecal reactivity for myelin
components precedes development of neurological symptoms in AIDS
patients. Arch Med Res 1997, 28:391-396.
12. Reindl M, Khalil M, Berger T: Antibodies as biological markers for
pathophysiological processes in MS. J Neuroimmunol 2006, 180:50-62.
13. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C: T-and B-cell
responses to myelin oligodendrocyte glycoprotein in experimental
autoimmune encephalomyelitis and multiple sclerosis. Glia 2001,
36:220-234.
14. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al:
Antibodies to native myelin oligodendrocyte glycoprotein in children
with inflammatory demyelinating central nervous system disease. Ann
Neurol 2009, 66:833-842.
15. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S,
et al: Age-dependent B cell autoimmunity to a myelin surface antigen in
pediatric multiple sclerosis. J Immunol 2009, 183:4067-4076.
16. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al:
Self-antigen tetramers discriminate between myelin autoantibodies to
native or denatured protein. Nat Med 2007, 13:211-217.
17. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W, et al:
Identification of a pathogenic antibody response to native myelin
oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA
2006, 103:19057-19062.
18. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, et al:
Antibodies against the myelin oligodendrocyte glycoprotein and the
myelin basic protein in multiple sclerosis and other neurological
diseases: a comparative study. Brain 1999, 122(Pt 11):2047-2056.
19. Wang H, Munger KL, Reindl M, O’Reilly EJ, Levin LI, Berger T, et al: Myelin
oligodendrocyte glycoprotein antibodies and multiple sclerosis in
healthy young adults. Neurology 2008, 71:1142-1146.
20. Power C, Selnes OA, Grim JA, McArthur JC: HIV Dementia Scale: a rapid
screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:273-278.
21. Pittock SJ, Reindl M, Achenbach S, Berger T, Bruck W, Konig F, et al: Myelin
oligodendrocyte glycoprotein antibodies in pathologically proven
multiple sclerosis: frequency, stability and clinicopathologic correlations.
Mult Scler 2007, 13:7-16.
22. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ: Changes to AIDS
dementia complex in the era of highly active antiretroviral therapy. AIDS
1999, 13:1249-1253.
23. Speth C, Dierich MP, Sopper S: HIV-infection of the central nervous
system: the tightrope walk of innate immunity. Mol Immunol 2005,
42:213-228.
24. Reboul J, Schuller E, Pialoux G, Rey MA, Lebon P, Allinquant B, et al:
Immunoglobulins and complement components in 37 patients infected
by HIV-1 virus: comparison of general (systemic) and intrathecal
immunity. J Neurol Sci 1989, 89:243-252.
25. Maimone D, Annunziata P, Cioni C, Leonardi A, Guazzi GC: Intrathecal
synthesis of anti-myelin basic protein IgG in HIV-1+ patients. Acta Neurol
Scand 1994, 90:285-292.
26. Mastroianni CM, Liuzzi GM, Jirillo E, Vullo V, Delia S, Riccio P: Cerebrospinal
fluid markers for the monitoring of AIDS dementia complex severity:
usefulness of anti-myelin basic protein antibody detection. AIDS 1991,
5:464-465.
27. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St CM,
et al: Relationship between human immunodeficiency virus-associated
dementia and viral load in cerebrospinal fluid and brain. Ann Neurol
1997, 42:689-698.
28. Eggers C, Hertogs K, Sturenburg HJ, van LJ, Stellbrink HJ: Delayed central
nervous system virus suppression during highly active antiretroviral
therapy is associated with HIV encephalopathy, but not with viral drug
resistance or poor central nervous system drug penetration. AIDS 2003,
17:1897-1906.
29. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M: Immune
activation of the central nervous system is still present after > 4 years of
effective highly active antiretroviral therapy. J Infect Dis 2007,
196:1779-1783.
30. Venkataramana A, Pardo CA, McArthur JC, Kerr DA, Irani DN, Griffin JW, et al:
Immune reconstitution inflammatory syndrome in the CNS of HIV-
infected patients. Neurology 2006, 67:383-388.
31. Khalil M, Reindl M, Lutterotti A, Kuenz B, Ehling R, Gneiss C, et al: Epitope
specificity of serum antibodies directed against the extracellular domain
of myelin oligodendrocyte glycoprotein: Influence of relapses and
immunomodulatory treatments. J Neuroimmunol 2006, 174:147-156.
32. Linares D, Echevarria I, Mana P: Single-step purification and refolding of
recombinant mouse and human myelin oligodendrocyte glycoprotein
and induction of EAE in mice. Protein Expr Purif 2004, 34:249-256.
33. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, et al:
Structural insights into the antigenicity of myelin oligodendrocyte
glycoprotein. Proc Natl Acad Sci USA 2003, 100:9446-9451.
34. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH: Pathogenic myelin
oligodendrocyte glycoprotein antibodies recognize glycosylated
epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA
2005, 102:13992-13997.
doi:10.1186/1742-2094-7-79
Cite this article as: Lackner et al.: Antibodies to myelin oligodendrocyte
glycoprotein in HIV-1 associated neurocognitive disorder: a cross-
sectional cohort study. Journal of Neuroinflammation 2010 7:79.
Lackner et al. Journal of Neuroinflammation 2010, 7:79
http://www.jneuroinflammation.com/content/7/1/79
Page 8 of 8